SBH
TVTX icon

Segall Bryant & Hamill’s Travere Therapeutics TVTX Stock Holding History

Segall Bryant & Hamill’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$805K Sell
27,101
-86
-0.3% -$2.57K 0.01% 530
2025
Q4 		$1.04M Buy
+27,187
New +$884K 0.01% 503

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Segall Bryant & Hamill's TVTX Position: Q1 2026 in Review

Segall Bryant & Hamill reduced its Travere Therapeutics (TVTX) stake by 0.32% in Q1 2026, selling an estimated $2.57K and leaving 27,101 shares worth $805K. The position accounts for 0.01% of the portfolio, ranked #530.

Segall Bryant & Hamill first reported a position in TVTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.04M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Segall Bryant & Hamill held 27,101 shares of Travere Therapeutics worth $805K as of Q1 2026.
  • Segall Bryant & Hamill sold 86 Travere Therapeutics shares in Q1 2026, an estimated $2.57K.
  • Travere Therapeutics made up 0.01% of Segall Bryant & Hamill's portfolio in Q1 2026, its #530 holding.
  • Segall Bryant & Hamill first reported a position in Travere Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Segall Bryant & Hamill's Travere Therapeutics position peaked at $1.04M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Segall Bryant & Hamill's 13F filing for Q1 2026, filed 15 May 2026.